Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
Cryptococcal Meningitis
About this trial
This is an interventional treatment trial for Cryptococcal Meningitis focused on measuring Cryptococcal meningitis
Eligibility Criteria
Inclusion criteria: Male or non-pregnant female who is >18 years old, HIV-positive or unknown, with acute, either first or recurrent episode of cryptococcal meningitis Currently on no treatment, or receiving treatment (< 3 days) with either amphotericin B plus 5-flucytosine, or amphotericin B alone. Positive CSF culture for Cryptococcus neoforman. Physical signs and symptoms of meningitis, evidenced by one or more of the following: fever, headache, meningeal signs and neurologic findings. Exclusion criteria: Excluded for coma, or significant other medical conditions. Subject has other opportunistic fungal infections that requires other systemic antifungal therapies. Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- University of Alabama School of Medicine
- Department of Medicine/Infectious Disease, MC 7881, University of Texas Health Science Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
Mycograb
biological